Dissecting the VEGFC–VEGFR-3 Pathway in NASH-Related Fibrosis: Insights from Naringin and SAR131675 Interventions

Study Background and Research Question

Non-alcoholic fatty liver disease (NAFLD), also termed metabolic dysfunction-associated fatty liver disease (MAFLD), is a major cause of cirrhosis and hepatocellular carcinoma globally. Within this spectrum, non-alcoholic steatohepatitis (NASH) is defined by hepatic steatosis, necroinflammation, and progressive fibrosis, ultimately leading to end-stage liver complications. Recent clinical and preclinical evidence has implicated vascular endothelial growth factor C (VEGFC) and its receptor VEGFR-3 in the regulation of hepatic inflammation, fibrosis, and macrophage function in NASH (source: reference_paper).

The featured study addresses a critical gap: Does downregulation of VEGFC contribute to the anti-fibrotic effects of naringin, and what are the underlying cellular mechanisms involving the hepatocyte–macrophage axis?

Key Innovation from the Reference Study

This work advances the field by systematically demonstrating that therapeutic targeting of the VEGFC–VEGFR-3 pathway—using both naringin and the selective VEGFR-3 inhibitor SAR131675—ameliorates liver fibrosis in a high-fat diet (HFD)-induced mouse model of NASH. The study uniquely combines pharmacological inhibition, genetic knockout models, and human clinical data to unravel how hepatocyte-derived VEGFC orchestrates macrophage recruitment and phenotypic switching, which are pivotal for fibrogenesis (source: reference_paper).

Methods and Experimental Design Insights

The multi-pronged experimental design incorporates:

• In vivo NASH model: Mice were fed a high-fat diet for 24 weeks to induce hepatic fibrosis, with interventions (naringin at 25 or 50 mg/kg/day, or SAR131675 at 30 mg/kg/day) administered from week 9 to 24, simulating a therapeutic regimen (source: reference_paper).
• Clinical cohort: Serum VEGFC levels were quantified in 165 patients with NAFLD/NASH, and hepatic VEGFC expression was analyzed using GEO datasets (GSE162694, GSE130970).
• Genetic models: Hepatocyte-specific Vegfc knockout mice were generated via crossing Vegfc^flox/flox with Alb-CreERT2 lines, enabling precise assessment of hepatocyte-derived VEGFC's role in fibrosis.
• In vitro assays: AML12 hepatocytes were pretreated with oleic acid, recombinant VEGFC, or subjected to Vegfc genetic modulation. These cells or their conditioned medium were then used to stimulate bone marrow-derived macrophages (BMDMs) to study migration and phenotypic transitions (source: reference_paper).

Protocol Parameters

• HFD-induced NASH mouse model | 24 weeks HFD, interventions from week 9–24 | preclinical fibrosis studies | recapitulates progressive liver injury and fibrosis | reference_paper
• Naringin dosing | 25–50 mg/kg/day, oral | anti-fibrotic effect assessment | dose-response evaluation in vivo | reference_paper
• SAR131675 dosing | 30 mg/kg/day, oral | VEGFR-3 pathway inhibition | tests anti-lymphangiogenic compound efficacy | reference_paper
• Serum VEGFC quantification | ELISA | clinical correlation studies | links circulating VEGFC to disease severity | reference_paper
• AML12 hepatocyte stimulation | oleic acid 0.5 mM, 24–48 h | in vitro steatosis modeling | mimics lipotoxic stress in hepatocytes | workflow_recommendation

Core Findings and Why They Matter

The study's chief discoveries are:

• Naringin and SAR131675 both suppressed liver inflammation and fibrosis in HFD-fed mice, evidenced by reduced serum transaminases, lower collagen deposition, and improved liver histology (source: reference_paper).
• VEGFC levels were elevated in both clinical NAFLD/NASH patients and HFD-fed mice, supporting translational relevance.
• Pharmacologic (SAR131675) or genetic (Vegfc^Hep-cKO) disruption of the VEGFC–VEGFR-3 axis recapitulated the beneficial effects of naringin, indicating that suppression of this signaling is central to anti-fibrotic action.
• Mechanistically, hepatocyte-derived VEGFC promoted macrophage migration via VEGFR-3 and CCL2/CCR2, and suppressed the phenotypic switch from pro-inflammatory Ly6C^high to reparative Ly6C^low macrophages via regulation of IL-10 and CX3CR1. Naringin disrupted this axis by lowering hepatocyte VEGFC output (source: reference_paper).

These findings underscore the therapeutic potential of anti-lymphangiogenic agents—and specifically, selective VEGFR-3 inhibitors—in modulating the hepatic immune microenvironment and fibrogenic processes in NASH.

Comparison with Existing Internal Articles

Several internal resources provide complementary insights into the mechanistic and translational roles of VEGFR-3 inhibition in fibrosis and cancer models. For instance, one review highlights SAR131675's exceptional selectivity and nanomolar potency, making it a benchmark tool for dissecting lymphangiogenesis and angiogenesis in preclinical models. Another thought-leadership article discusses SAR131675's advantages for strategic experimental design, noting its minimal off-target effects and robust anti-angiogenic profile. These analyses reinforce the current study's approach: deploying highly selective anti-angiogenic compounds such as SAR131675 enables precise investigation of VEGFR-3-mediated pathways in both cancer and fibrotic liver disease contexts.

What distinguishes the reference paper is its focus on the hepatocyte–macrophage axis in NASH, and its integration of clinical, genetic, and pharmacologic evidence to establish VEGFC/VEGFR-3 as a nodal driver of liver fibrosis, thus extending the translational relevance of VEGFR-3 inhibition beyond oncology and into metabolic liver pathology.

Limitations and Transferability

Some limitations merit consideration:

• The HFD-induced NASH model, while recapitulating key aspects of human disease, does not fully capture the complexity and chronicity of human NASH-fibrosis progression (source: reference_paper).
• Naringin's pleiotropic actions may confound attribution of all observed effects solely to VEGFC suppression.
• The long-term safety of pharmacologic VEGFR-3 inhibition remains unresolved; SAR131675, despite its selectivity, was discontinued due to adverse metabolic effects in preclinical studies (source: product_spec).
• Translational applicability to human NASH will require validation in diverse patient populations and consideration of compensatory lymphangiogenic and inflammatory pathways.

Research Support Resources

For researchers seeking to interrogate the VEGFC–VEGFR-3 axis in hepatic fibrosis, tumor biology, or lymphangiogenesis studies, SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor (SKU B2301, APExBIO), is available as a preclinical tool. Its high selectivity and nanomolar potency make it suitable for dissecting VEGFR-3 signaling in vivo and in vitro, as demonstrated in both the present study and related preclinical models (source: internal_article). Caution is advised with respect to solubility, handling, and long-term storage conditions, and researchers should be aware of the reported adverse metabolic findings associated with chronic administration (source: product_spec).